# Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

> **NCT04602273** · — · UNKNOWN · sponsor: **Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias** · enrollment: 150 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine Injection [Vidaza]

## Key facts

- **NCT ID:** NCT04602273
- **Lead sponsor:** Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-12
- **Primary completion:** 2020-11-01
- **Final completion:** 2021-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-10-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602273, "Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04602273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*